Ceptasom Dsr contains Esomeprazole. Ceptasom Dsr uses:
Ceptasom Dsr is indicated:
|Brand Name:||Ceptasom Dsr|
|Therapeutic Class:||Proton Pump Inhibitor|
|Manufacturer:||INCEPTA PHARMACEUTICALS LTD|
|Last Updated:||2020-11-20 18:15:00|
Ceptasom Dsr contains Esomeprazole 40.0 Mg. Ceptasom Dsr doses
Healing of erosive esophagitis: 20 mg or 40 mg once daily for 4 to 8 Weeks. For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8 weeks course of Ceptasom Dsr may be considered.
Long-term management of esophagitis: 20 mg once daily.
Symptomatic gastroesophageal reflux disease: 20 mg once daily for 4 weeks.
H. pylori eradication for treatment of duodenal ulcer:
Triple therapy: 20 mg Ceptasom Dsr once daily with 500 mg Clarithromycin twice daily, and 1 g Amoxicillin twice daily for 7-10 days.
The recommended adult dose in GERD with Erosive Esophagitis is either 20 or 40 mg Ceptasom Dsr given once daily by intravenous injection (no less than 3 minutes) or intravenous infusion (10 to 30 minutes). Pediatric dose (1 to 11 years old):
Healing of erosive esophagitis:
Directions for reconstitution of solution: Solution for injection is prepared by adding 5 ml of 0.9% Sodium Chloride for intravenous injection into the vial containing the dry powder. The reconstituted solution for injection is clear and colorless to very slightly yellow.
Preparations for Use and Administration of Ceptasom Dsr 40 IV Injection: A solution for intravenous infusion is prepared by first reconstituting the contents of one vial with 5 ml of 0.9% Sodium Chloride and further diluting the resulting solution to a final volume of 50 ml. The resultant concentration after diluting to a final volume of 50 ml is 0.8 mg/ml.
In general, esomeprazole is well tolerated in both short and long term use. Adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth.
Ceptasom Dsr is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
Symptomatic response to therapy with Ceptasom Dsr does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which Ceptasom Dsr is an enantiomer.
Drug interaction studies have shown that Esomeparzole does not have any clinically significant interactions with Phenytoin, Warfarin, Quinidine, Clarithromycin or Amoxicillin. Ceptasom Dsr inhibits gastric acid secretion. Therefore, Ceptasom Dsr may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, Ketoconazole, Iron salts and Dogoxin). Coadministration of oral contraceptives, Diazepam, Phenytoin or Quinidine did not seem to change the pharmacokinetic profile of Ceptasom Dsr.
Pregnancy: There are no adequate and well-controlled studies on the use of Ceptasom Dsr in pregnant women. Therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk. Ceptasom Dsr should be used during pregnancy only if the potential benefit to pregnant women justifies the potential risk to the fetus.
Lactation: Ceptasom Dsr is excreted in human milk. Thus, a decision should be taken to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Ceptasom Dsr is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
Geriatric: Dosage adjustment is not necessary.
Pediatric: Safety and effectiveness in pediatric patients have not been established.
Hepatic insufficiency: No dosage adjustment is recommended for patients with mild to moderate hepatic insufficiency. However, in patients with severe hepatic insufficiency a dose of 20 mg once daily should not be exceeded.
Renal insufficiency: Dosage adjustment is not necessary.
There is no experience to data with deliverate overdose. Data are limited but single doses of 80 mg Ceptasom Dsr were uneventful. Ceptasom Dsr is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.
Store between 15-30°C. Protect from light.
Ceptasom Dsr Capsule price in India 0